Joshi, Kroopa
,
de Massy, Marc Robert http://orcid.org/0000-0002-3048-1680
Ismail, Mazlina
Reading, James L.
Uddin, Imran http://orcid.org/0000-0003-0736-3149
Woolston, Annemarie http://orcid.org/0000-0002-8932-2895
Hatipoglu, Emine
Oakes, Theres
Rosenthal, Rachel
Peacock, Thomas http://orcid.org/0000-0001-9385-116X
Ronel, Tahel
Noursadeghi, Mahdad http://orcid.org/0000-0002-4774-0853
Turati, Virginia
Furness, Andrew J. S.
Georgiou, Andrew
Wong, Yien Ning Sophia
Ben Aissa, Assma
Sunderland, Mariana Werner
Jamal-Hanjani, Mariam
Veeriah, Selvaraju
Birkbak, Nicolai J.
Wilson, Gareth A.
Hiley, Crispin T.
Ghorani, Ehsan http://orcid.org/0000-0001-5373-5762
Guerra-Assunção, José Afonso http://orcid.org/0000-0001-6593-403X
Herrero, Javier http://orcid.org/0000-0001-7313-717X
Enver, Tariq
Hadrup, Sine R. http://orcid.org/0000-0002-5937-4344
Hackshaw, Allan
Peggs, Karl S.
McGranahan, Nicholas
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
Chain, Benny http://orcid.org/0000-0002-7417-3970
Funding for this research was provided by:
Cancer Research UK (C33499/A20265, A24314, TRACERx)
DH | National Institute for Health Research (BCR)
Rosetrees Trust
DH | National Institute for Health Research (BCR)
Royal Marsden NHS Foundation Trust
Article History
Received: 2 May 2019
Accepted: 20 August 2019
First Online: 7 October 2019
Change Date: 3 June 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: C.S. receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana and Boehringer-Ingelheim. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute and is an adviser for Dynamo Therapeutics. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options in and is co-founder of Achilles Therapeutics. S.A.Q. is a co-founder of Achilles Therapeutics. R.R., N.M. and G.A.W. have stock options in and have consulted for Achilles Therapeutics. J.L.R. has consulted for Achilles Therapeutics.